Navigation Links
Lilly Recognized as One of the World's Top Biopharmaceutical Employers
Date:10/10/2008

f Eli Lilly and Company, and this acknowledgement underscores Lilly's commitment to our employees and the patients we serve."

Approximately 25 percent of Lilly's 2007 sales came from biotech medicines; this makes the biotech portion of the company's business the equivalent of the world's fifth largest biotech company. Biotech molecules also represent approximately one-third of the company's current pipeline including potential treatments targeting Alzheimer's disease, cancer and diabetes.

About Science

Published by the American Association for the Advancement of Science (AAAS), Science ranks as the world's largest general science journal. Each week, Science provides more than 130,000 global subscribers with peer-reviewed original research, scientific research articles, science and research news and more. Science also produces a freely accessible careers website, ScienceCareers.org, offering thousands of job listings, career advice and more.

About Lilly

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at http://www.lilly.com.

C-LLY

(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Emisphere Technologies, Inc. and Eli Lilly and Company Settle Ongoing Litigation
2. Lilly Declares Fourth-Quarter Dividend
3. Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar
4. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
5. Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration
6. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
7. Lilly Announces Termination of AIR Insulin Program
8. HistoRx and Lilly Extend, Expand AQUA(R) Analysis Partnership
9. Pelikan Technologies and Lilly Form Alliance to Promote Diabetes Education
10. Lilly Reports Solid First-Quarter Results
11. Lilly CEO Praises Massachusetts Leadership in Biotech, Urges Policy Prescriptions to Help Ensure States Investment Generates Dividends and Jobs
Post Your Comments:
*Name:
*Comment:
*Email: